Pfizer will list its COVID-19 treatment Paxlovid at a price of $1,390 per five-day course when it soon hits the commercial market, the drugmaker confirmed to Axios.

Why it matters: Paxlovid’s new listed price, first reported by the Wall Street Journal, will be more than twice the $529 paid by the federal government, which until now has maintained the entire U.S. supply of the key antiviral medication.

  • Stuka@lemmy.ml
    link
    fedilink
    arrow-up
    4
    ·
    1 year ago

    Honestly 1400 for a 5 day course of this is more reasonable than I expected. It’s still unreasonable, but I just figured it’s be way higher.